RLYB vs. OTLK, BMEA, IMRX, OKYO, IKNA, CUE, PRLD, ATNM, CELU, and STTK
Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Outlook Therapeutics (OTLK), Biomea Fusion (BMEA), Immuneering (IMRX), OKYO Pharma (OKYO), Ikena Oncology (IKNA), Cue Biopharma (CUE), Prelude Therapeutics (PRLD), Actinium Pharmaceuticals (ATNM), Celularity (CELU), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry.
Rallybio vs.
Outlook Therapeutics (NASDAQ:OTLK) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends.
Outlook Therapeutics' return on equity of 0.00% beat Rallybio's return on equity.
In the previous week, Outlook Therapeutics had 4 more articles in the media than Rallybio. MarketBeat recorded 5 mentions for Outlook Therapeutics and 1 mentions for Rallybio. Outlook Therapeutics' average media sentiment score of 0.76 beat Rallybio's score of 0.00 indicating that Outlook Therapeutics is being referred to more favorably in the media.
Outlook Therapeutics received 121 more outperform votes than Rallybio when rated by MarketBeat users. However, 73.33% of users gave Rallybio an outperform vote while only 71.12% of users gave Outlook Therapeutics an outperform vote.
Rallybio has higher revenue and earnings than Outlook Therapeutics. Outlook Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.
Outlook Therapeutics currently has a consensus target price of $10.20, indicating a potential upside of 507.14%. Rallybio has a consensus target price of $10.00, indicating a potential upside of 2,903.00%. Given Rallybio's higher possible upside, analysts clearly believe Rallybio is more favorable than Outlook Therapeutics.
Outlook Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.28, suggesting that its share price is 228% less volatile than the S&P 500.
11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 4.8% of Outlook Therapeutics shares are held by insiders. Comparatively, 8.7% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Outlook Therapeutics and Rallybio tied by winning 8 of the 16 factors compared between the two stocks.
Get Rallybio News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rallybio Competitors List
Related Companies and Tools
This page (NASDAQ:RLYB) was last updated on 5/21/2025 by MarketBeat.com Staff
